Uncertainty and Opportunity
May 31, 2022
By Ryan M. Thomas
The uncertain times continue.
Since the founding of Eyam in 2020, we’ve experienced a pandemic, an unprecedented lockdown, mass riots and looting, a contested US Presidential election, historically high inflation, Putin’s invasion of Ukraine, food and energy shortages, and now significant volatility in the stock market.
In lesser covered news, we’re also in the middle of a historic bird flu outbreak that is killing nearly 100% of infected chickens, and – only since January – wiping out more than 10% (35 million) of chickens in the US alone.
This avian influenza outbreak has now begun to be detected in other species, including one known human infection, as spillover events are now occurring. One clear consequence of this outbreak is the more than 160% increase in the cost of eggs and 70% increase in the cost of poultry which adversely affect developing nations and those living in poverty as poultry is counted on as a low-cost source of protein.
This outbreak is another reminder of the importance of securing faster and better vaccine design and production – for both humans and animals. Just as nations are waking up to the national security threats of not having advanced defense capabilities, it’s also become clear that each country needs to also have access to safe and effective vaccines that can be produced in-country.
In the midst of all of this uncertainty lies significant opportunities for Eyam.
As a refresher, Eyam’s proprietary bioinformatics platform, the Jennerator, uses sophisticated algorithms and machine learning to design vaccines in a fraction of the time as Big Pharma. This Jennerator takes into account “big data” from viruses and immune system markers to design vaccines for universal protection and coverage. Eyam’s proprietary self-amplifying technology also reduces the amount of mRNA in a vaccine by up to 1/1000 of first generation mRNA vaccines which means lower cost, faster manufacturing times, and better protein expression for optimal immune system protection.
No matter what happens in Ukraine, or the stock market, the demand for innovative and disruptive vaccine and therapeutic technologies will continue to increase. While much of the world has been socially distancing, old diseases that were hiding during the first two years of the pandemic are back and behaving in new and unexpected ways, closer contact with wild animals is increasing the probability of novel viruses jumping into humans, and the threat of escaped lab experiments or biological warfare is always a possibility.
While uncertainty abounds, here at Eyam, we continue to make significant progress on our milestones, validate our new technologies, and prepare our vaccines for clinical trials.
Uncertainty and Opportunity
May 31, 2022
By Ryan M. Thomas
The uncertain times continue.
Since the founding of Eyam in 2020, we’ve experienced a pandemic, an unprecedented lockdown, mass riots and looting, a contested US Presidential election, historically high inflation, Putin’s invasion of Ukraine, food and energy shortages, and now significant volatility in the stock market.
In lesser covered news, we’re also in the middle of a historic bird flu outbreak that is killing nearly 100% of infected chickens, and – only since January – wiping out more than 10% (35 million) of chickens in the US alone.
This avian influenza outbreak has now begun to be detected in other species, including one known human infection, as spillover events are now occurring. One clear consequence of this outbreak is the more than 160% increase in the cost of eggs and 70% increase in the cost of poultry which adversely affect developing nations and those living in poverty as poultry is counted on as a low-cost source of protein.
This outbreak is another reminder of the importance of securing faster and better vaccine design and production – for both humans and animals. Just as nations are waking up to the national security threats of not having advanced defense capabilities, it’s also become clear that each country needs to also have access to safe and effective vaccines that can be produced in-country.
In the midst of all of this uncertainty lies significant opportunities for Eyam.
As a refresher, Eyam’s proprietary bioinformatics platform, the Jennerator, uses sophisticated algorithms and machine learning to design vaccines in a fraction of the time as Big Pharma. This Jennerator takes into account “big data” from viruses and immune system markers to design vaccines for universal protection and coverage. Eyam’s proprietary self-amplifying technology also reduces the amount of mRNA in a vaccine by up to 1/1000 of first generation mRNA vaccines which means lower cost, faster manufacturing times, and better protein expression for optimal immune system protection.
No matter what happens in Ukraine, or the stock market, the demand for innovative and disruptive vaccine and therapeutic technologies will continue to increase. While much of the world has been socially distancing, old diseases that were hiding during the first two years of the pandemic are back and behaving in new and unexpected ways, closer contact with wild animals is increasing the probability of novel viruses jumping into humans, and the threat of escaped lab experiments or biological warfare is always a possibility.
While uncertainty abounds, here at Eyam, we continue to make significant progress on our milestones, validate our new technologies, and prepare our vaccines for clinical trials.
